Works by Lantto, Johan

Results: 7

Non-germ-line encoded residues are critical for effective antibody recognition of a poorly immunogenic neutralization epitope on glycoprotein B of human cytomegalovirus.

Published in:

European Journal of Immunology, 2002, v. 32, n. 6, p. 1659, doi. 10.1002/1521-4141(200206)32:6<1659::AID-IMMU1659>3.0.CO;2-9

By:

Lantto, Johan;
Lindroth, Ylva;
Ohlin, Mats

Publication type:

Article

Uneven Distribution of Repetitive Trinucleotide Motifs in Human Immunoglobulin Heavy Variable Genes.

Published in:

Journal of Molecular Evolution, 2002, v. 54, n. 3, p. 346, doi. 10.1007/s00239-001-0049-2

By:

Lantto, Johan;
Ohlin, Mats

Publication type:

Article

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.

Published in:

2017

By:

Schwarz, Luis J;
Hutchinson, Katherine E;
Rexer, Brent N;
Estrada, Mónica Valeria;
Gonzalez Ericsson, Paula I;
Sanders, Melinda E;
Dugger, Teresa C;
Formisano, Luigi;
Guerrero-Zotano, Angel;
Red-Brewer, Monica;
Young, Christian D;
Lantto, Johan;
Pedersen, Mikkel W;
Kragh, Michael;
Horak, Ivan D;
Arteaga, Carlos L

Publication type:

journal article

Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.

Published in:

2019

By:

Gjetting, Torben;
Gad, Monika;
Fröhlich, Camilla;
Lindsted, Trine;
Melander, Maria C;
Bhatia, Vikram K;
Grandal, Michael M;
Dietrich, Nikolaj;
Uhlenbrock, Franziska;
Galler, Gunther R;
Strandh, Magnus;
Lantto, Johan;
Bouquin, Thomas;
Horak, Ivan D;
Kragh, Michael;
Pedersen, Mikkel W;
Koefoed, Klaus

Publication type:

Report

Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.

Published in:

International Journal of Cancer, 2016, v. 139, n. 9, p. 2095, doi. 10.1002/ijc.30242

By:

Ellebæk, Sofie;
Brix, Susanne;
Grandal, Michael;
Lantto, Johan;
Horak, Ivan D.;
Kragh, Michael;
Poulsen, Thomas Tuxen

Publication type:

Article

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.

Published in:

2020

By:

Reddy, Tejaswini P.;
Choi, Dong S.;
Anselme, Ann C.;
Qian, Wei;
Chen, Wen;
Lantto, Johan;
Horak, Ivan D.;
Kragh, Michael;
Chang, Jenny C.;
Rosato, Roberto R.

Publication type:

journal article

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 586, doi. 10.1007/s10637-022-01217-7

By:

Berlin, Jordan;
Tolcher, Anthony W.;
Ding, Cliff;
Whisenant, Jennifer G.;
Horak, Ivan D.;
Wood, Debra L.;
Nadler, Paul I.;
Hansen, Ulla Holm;
Lantto, Johan;
Skartved, Niels Jørgen Ø.;
Pedersen, Mikkel W.;
Patnaik, Amita

Publication type:

Article